Please login to the form below

Not currently logged in
Email:
Password:

Elan promotes president of R&D to board

Irish biotech Elan has hired Dr Lars Ekman, who is currently president of R&D, to the position of member of the operating committee and the board of directors

Irish biotech Elan has hired Dr Lars Ekman, who is currently president of R&D, to the position of member of the operating committee and the board of directors.

Dr Ekman will transition from his current operational role to become an advisor as a member of the board of directors from 31 December 2007. He will continue to chair the science and technology committee on matters relating to Elan's research platform and portfolio. Other board members include Dr Dennis Selkoe and Dr Floyd Bloom.

Ekman will remain an integral part of the company's science, clinical development and corporate activities and will continue as key senior spokesperson for Elan as president of R&D. He will also continue as co-chair on the joint steering committee with US-based pharmaceutical company Wyeth. Ekman's responsibility will be to focus on Elan's intermediate and long-term plans as he dedicates his time to provide strategic advice to the chairman and the CEO in his continuing role as a member of the board of directors.

Ekman joined Elan in January 2001 after holding a number of senior executive positions in the pharmaceutical industry. During this period, Elan received approval for four US NDAs, three EU marketing approval applications and five iNDAs. His efforts have seen the drugs Prialt and Tysabri come to market and progressing further several of Elan's Alzheimer's immunotherapy programmes.

9th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics